Drug reference

Acamprosate calcium

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 540

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Maintenance of abstinence in alcohol-dependent patients ▶BY MOUTH ▶Adult 18–65 years (body-weight up to 60 kg): 666 mg once daily at breakfast and 333 mg twice daily at midday and at night ▶Adult 18–65 years (body-weight 60 kg and above): 666 mg 3 times a day

PDF page 540

Cautions

Continued alcohol abuse (risk of treatment failure)

PDF page 540

Prescribing And Dispensing Information

Acamprosate calcium has been used for the maintenance of abstinence in alcohol dependence in children aged 16 years and over.

PDF page 540

Safety

Side Effects

▶Common or very common Abdominal pain. diarrhoea. ﬂatulence. nausea. sexual dysfunction. skin reactions. vomiting

PDF page 540

Pregnancy

Manufacturer advises avoid unless potential beneﬁt outweighs risk.

PDF page 540

Breast Feeding

Avoid.

PDF page 540

Hepatic Impairment

Manufacturer advises caution in severe hepatic failure—no information available.

PDF page 540

Renal Impairment

Avoid if serum-creatinine greater than 120 micromol/litre.

PDF page 540

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Gastro-resistant tablet CAUTIONARY AND ADVISORY LABELS 5, 21, 25 ELECTROLYTES: May contain Calcium ▶Acamprosate calcium (Non-proprietary) Acamprosate calcium 333 mg Acamprosate 333mg gastro-resistant tablets | 168 tablet P £38.25 DT = £38.14 ▶Campral EC (Merck Serono Ltd) Acamprosate calcium 333 mg Campral EC 333mg tablets | 168 tablet P £28.80 DT = £38.14 OPIOID RECEPTOR ANTAGONISTS

PDF page 540

Dose text by age group

Adult 18–65 years (body-weight up to 60 kg)

666 mg once

First-line fragment. Read the complete Indications and Dose section above.

PDF page 540

Adult 18–65 years (body-weight 60 kg and above)

666 mg

First-line fragment. Read the complete Indications and Dose section above.

PDF page 540

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Acamprosate calcium

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 540

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 540

Cautions

Continued alcohol abuse (risk of treatment failure)

PDF page 540

Prescribing And Dispensing Information

Acamprosate calcium has been used for the maintenance of abstinence in alcohol dependence in children aged 16 years and over.

PDF page 540

Safety

Side Effects

▶Common or very common Abdominal pain. diarrhoea. ﬂatulence. nausea. sexual dysfunction. skin reactions. vomiting

PDF page 540

Pregnancy

Manufacturer advises avoid unless potential beneﬁt outweighs risk.

PDF page 540

Breast Feeding

Avoid.

PDF page 540

Hepatic Impairment

Manufacturer advises caution in severe hepatic failure—no information available.

PDF page 540

Renal Impairment

Avoid if serum-creatinine greater than 120 micromol/litre.

PDF page 540

Dose and formulations

Medicinal Forms

PDF page 540

Dose text by age group

Adult 18–65 years (body-weight up to 60 kg)

666 mg once

First-line fragment. Read the complete Indications and Dose section above.

PDF page 540

Adult 18–65 years (body-weight 60 kg and above)

666 mg

First-line fragment. Read the complete Indications and Dose section above.

PDF page 540

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.